01—Abstract
Summary
Summary of the 10-K filed February 19, 2021. Cited figures are marked; the original filing is the authoritative source.
HCA Healthcare's 2020 10-K shows a company that absorbed a severe COVID-19 volume shock while still growing net income.
Revenue rose 0.4% to $51.5 billiona, but equivalent admissions fell 9.2% and same-facility revenue slipped 0.1%; the revenue stability came from a 10.5% increase in revenue per equivalent admission, driven by higher acuity and reimbursement mix. Net income attributable to HCA rose 7.1% to $3.754 billion, or $10.93 per diluted share, helped by a $60 million employee retention tax credit, lower interest expense ($1.584 billion versus $1.824 billion), and a $112 million reduction in professional liability provisions. Operating cash flow increased to $9.232 billion, driven partly by working capital gains and $688 million of deferred Social Security taxes.
The balance sheet remains highly leveraged. Total debt was $31.0 billionb at year-end, down from $33.7 billion, and stockholders' equity turned positive at $2.9 billion total (including noncontrolling interests) after a deficit in 2019. Management returned about $6.1 billion of CARES Act Provider Relief Fund and accelerated Medicare payments during Q4 2020, which signals confidence but also reflects that the funds were not retained as earnings.
Capital allocation was defensive during the year: capex fell to $2.8 billionc from $4.2 billion, buybacks were suspended and then resumed in February 2021 with $8.8 billion of total authorization, and the dividend was reinstated at $0.48 per quarter after a 2020 suspension. Key risks for investors include geographic concentration (Florida and Texas generate 49% of revenue and house 91 of 185 hospitals), reliance on government programs (42.7% of revenue from Medicare and Medicaid), the expiration of the Public Health Emergency and uncertain federal policy under the new administration, and the potential for a COVID-19 resurgence. The filing also notes uncertainty over the Affordable Care Act, site-neutral payment policy, and LIBOR transition, plus a pending qui tam lawsuit in Texas related to the Medicaid supplemental program.
02—Key points
Key Highlights
- Revenue of $51.533 billion (+0.4%) despite a 9.2% decline in equivalent admissions, offset by a 10.5% increase in revenue per equivalent admission
- Net income attributable to HCA of $3.754 billion ($10.93 diluted EPS), up 7.1% from $3.505 billion ($10.07), including a $60M CARES Act payroll tax credit and $112M favorable professional liability development
- Operating cash flow rose 21% to $9.232 billion, supported by $1.37 billion of favorable working capital changes and $688M of deferred Social Security taxes
- Total debt reduced to $31.0 billion from $33.7 billion; average interest rate on long-term debt declined to 5.0% from 5.3%, and interest expense fell $240M
- Returned roughly $6.1 billion of CARES Act Provider Relief Fund and accelerated Medicare payments in Q4 2020, while retaining $83M of unreturned partnership-level funds
- Capital expenditures reduced to $2.8 billion (from $4.2 billion); 2021 planned capex of about $3.7 billion signals a return to investment
- Capital return resumed in February 2021: quarterly dividend reinstated at $0.48 per share and total buyback authorization of $8.8 billion
- Florida and Texas account for 49% of revenue and 91 of 185 hospitals, creating meaningful geographic concentration risk
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 19, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $51.53B$51.34B | +0.4% |
| Operating Expenses | $46.10B$46.09B | 0.0% |
| Interest Expense | $1.58B$1.82B | −13.2% |
| Net Income | $3.75B$3.50B | +7.1% |
| EPS (Basic) | $11.10$10.27 | +8.1% |
| EPS (Diluted) | $10.93$10.07 | +8.5% |
| Shares Outstanding (Basic) | 338.27M341.21M | −0.9% |
| Shares Outstanding (Diluted) | 343.61M348.23M | −1.3% |
05—Questions
Frequently Asked Questions
Did HCA's COVID-19 volume declines materially hurt 2020 profitability?
Volumes fell sharply: admissions declined 4.7%, inpatient surgeries 7.8%, outpatient surgeries 12.6%, and emergency room visits 18.7%. Revenue held roughly flat because revenue per equivalent admission rose 10.5%, reflecting higher acuity of COVID-19 patients and payer mix shifts. Net income still grew, aided by lower interest expense, a one-time employee retention credit, and reserve releases. Management attributed the volume declines mainly to deferred care and reduced ER use, and described much of the impact as deferral rather than permanent demand loss, though it cannot guarantee recovery to pre-pandemic volumes.
How much government COVID-19 funding did HCA receive, and what happened to it?
HCA received about $4.4 billion in accelerated Medicare payments and about $1.8 billion in general and targeted Provider Relief Fund distributions during 2020. In October 2020 the company decided to return all of these funds, and it returned or repaid approximately $6.1 billion in Q4 2020. Only $83 million held by partnership entities remains on the balance sheet as an accrued liability, to be returned in 2021. The company also deferred $688 million of Social Security taxes, half payable by end-2021 and the rest by end-2022.
How leveraged is HCA, and how is it managing debt?
Total debt was $31.0 billion at December 31, 2020, down from $33.7 billion. The company issued $2.7 billion of 3.50% senior notes due 2030 and used proceeds to redeem higher-coupon notes, incurring a $295 million pretax loss on debt retirement. Available liquidity included $1.96 billion under the senior secured revolver and $3.75 billion under the ABL facility, with a $2.0 billion 364-day term loan terminated in January 2021. About $1.2 billion of debt is variable-rate, and a 1% rate increase would reduce pretax earnings by roughly $12 million. The filing flags that the company is highly leveraged and that its senior secured covenants restrict additional debt, dividends and asset sales.
What are the biggest policy and regulatory risks to HCA's revenue?
Government programs (Medicare and Medicaid) produced 42.7% of 2020 revenue, so reimbursement policy is central. Key risks include the 2% Medicare sequestration reduction (suspended through March 31, 2021, then scheduled to resume), site-neutral payment expansion reducing outpatient reimbursement, the 340B drug payment reduction, the planned use of Medicare Advantage median negotiated charges in MS-DRG weighting from 2024, and state Medicaid supplemental payment programs under CMS review. Texas supplemental waiver payments were $599 million in 2020. Uncertainty around the Affordable Care Act and possible Medicare-for-All proposals adds further risk. The company also faces an FCA qui tam lawsuit tied to the Texas Harris County Medicaid program.
Is the dividend and buyback program sustainable, and what constrains it?
The board reinstated the quarterly dividend at $0.48 per share in February 2021, up from $0.43 before the 2020 suspension, and authorized $6 billion of new buybacks, bringing total repurchase capacity to $8.8 billion. Payments are subject to capital availability, debt covenants that restrict restricted payments, and the board's judgment about strategic priorities such as acquisitions and capex. The company repurchased only $441 million of stock and paid $153 million in dividends in 2020, so the 2021 capital return program represents a substantial step-up. Investors should weigh this against roughly $31 billion of debt and the company's stated intention to reach capex of $3.7 billion in 2021.
06—Continue